Idorsia Secures Major Funding Boost Through Oversubscribed Share Placement

Swiss biopharmaceutical firm Idorsia Ltd has successfully completed a significantly oversubscribed capital raise, generating CHF 65.6 million. The company placed 16.4 million new shares at CHF 4 each, exceeding its initial placement target due to substantial institutional investor demand that signals growing market confidence in Idorsia’s strategic direction.

The capital increase was met with such robust demand that Idorsia expanded the offering from the originally planned 15 million shares to 16.4 million shares. Chief Financial Officer Arno Groenewoud expressed enthusiasm about the market response, stating, “This oversubscribed offering from high-quality institutional investors clearly demonstrates recognition of Idorsia’s substantial potential.”

The placement consisted of 12.9 million shares from authorized capital and 3.5 million shares from existing treasury holdings. The issuance price of CHF 4 per... Read more...